Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis

  title={Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis},
  author={Xu Zhao and Xiaofang Zhang and Yang Zhao and Xin Lin and Ning-yin Li and Ganesh Paudel and Qiongyin Wang and Xiao-wei Zhang and Xiu-li Li and Jing Yu},
  journal={Gynecological Endocrinology},
  pages={685 - 689}
Abstract Postmenopausal hypertensive is associated with estrogen deficiency. This meta-analysis was performed to assess the efficacy and safety of drospirenone combined with 17-β-estradiol (DRSP/E2) in postmenopausal hypertensive women. A systemic literature search of PubMed, Embase, Cochrane Library, Web of Science (up to Oct. 2015) was performed. Studies were screened independently by two researchers according to the inclusion and exclusion criteria which included only the randomized… Expand
Menopausal hyperinsulinism and hypertension – new approach
E2/DRSP represents suitable therapy for hyperinsulinemic, grade I hypertensive menopausal women with typical symptoms and normal weight. Expand
Hormones endogènes et exogènes
Before menopause, women are protected from the risk of hypertension and atherosclerosis by endogenous estrogens. Estrogens have a vasoprotective role, while progesterone seems to have a neutralExpand
Variations in Blood Pressure and Pulse Rate in Phases of Menstrual Cycle in women with Primary Dysmenorrhea
Introduction: Menstrual cycle include changes that occur at intervals in the uterus, ovaries, vagina during reproductive age to make procreation possible. The biological activity of the menstrualExpand
Hormonersatztherapie und Prävention gemäß S3-Leitlinie
Eine Hormonersatztherapie kann effektiv klimakterische Beschwerden lindern. Darüber hinaus hat sie Wirkungen, die sich positiv auf die Gesundheit auswirken, aber auch die Anwendung limitieren können.Expand
Uterine haemodynamic, vascularization and blood pressure changes along the oestrous cycle in bitches.
Hemodynamic changes in the uterine artery, uterine diameter, systemic blood pressure and heart rate occur during the canine oestrous cycle, while uterine blood flow diminishes during oestrus and anoestrus. Expand
Usporedba transdermalne i oralne primjene hormonskog nadomjesnog liječenja kod žena u postmenopauzi
Ovaj rad donosi pregled literature o slicnostima i razlikama oralne i transdermalne primjene hormonskog nadomjesnog lijecenja, poglavito estrogena,
Hormonersatztherapie und Prävention gemäß S3-Leitlinie
The effects are low and contradictory with respect to hormone-dependent tumors so that hormone replacement therapy is not suitable for oncological prophylaxis, and can effectively relieve climacteric complaints. Expand


Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril.
A significant additive BP-lowering effect of DRSP/E2 on both systolic and diastolic BP in hypertensive postmenopausal women receiving ENA is suggested, consistent with an antimineralocorticoid effect. Expand
Antihypertensive Effects of Drospirenone With 17&bgr;-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension
Combination therapy with DRSP/E2 significantly lowered both clinic and 24-hour systolic BP in postmenopausal women with stage 1 systolics hypertension, which may lead to benefit for cardiovascular risk reduction in this population of women. Expand
Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide
DRSP/E2 substantially lowers systolic and diastolic blood pressure when added to existing antihypertensive therapy with HCTZ in hypertensive postmenopausal women and has a potassium-sparing effect that counteracts HCTz-induced potassium loss. Expand
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
In hypertensive postmenopausal women, treatment with DRSP/E2 was not associated with a greater incidence of hyperkalemia than with placebo in patients with and without type 2 diabetes mellitus and concomitant use of ACE inhibitors, angiotensin receptor antagonists, or ibuprofen. Expand
Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens
It is demonstrated that the combinations of 1, 2, and 3’mg drospirenone with 1 mg estradiol are safe and effective for the treatment of climacteric symptoms. Expand
Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study
  • A. Paoletti, A. Cagnacci, +4 authors G. Melis
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2015
Differences between the two progestins are mainly limited to body composition (BC), where the addition of DRSP decreases ECW and body W (BW). Expand
One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women
The low-dose, 0.25 mg DRSP/0.5 mg E2 dose combination met the criteria for endometrial safety and demonstrated a favorable risk/benefit profile in this 1-year, double-blind, randomized study of postmenopausal women. Expand
Effects of a New Hormone Therapy, Drospirenone and 17-&bgr;-Estradiol, in Postmenopausal Women With Hypertension
Data show that DRSP combined with E2 significantly reduces BP in postmenopausal women with hypertension and did not induce significant increases in serum potassium, which may lead to a new benefit for this novel hormone therapy in postwomen's hypertension. Expand
Low-dose estrogen and drospirenone combination: effects on metabolism and endothelial function in postmenopausal women with metabolic syndrome.
Drospirenone improves cardiovascular risk factors and does not impair endothelial function in menopausal women with metabolic syndrome. Expand
Effects of estradiol–drospirenone on menopausal symptoms, lipids and bone turnover in Chinese women
  • M. Li, A. Wang, +5 authors X. Li
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2015
Estradiol–drospirenone effectively alleviates menopausal symptoms and also has beneficial effects on blood lipids and bone metabolism. Expand